Kadmos Capital is a UK-based venture capital fund focused on early-stage deep-tech companies with positive impact across artificial intelligence, sustainability and longevity.
The funding was co-led by Kadmos Capital and Clay Capital to expand the company's enzyme engine and wet-lab capabilities.
"Scindo represents exactly the type of company we seek to back – one that combines data-driven approaches with strong technical talent to address sustainability challenges,"
The financing round was led by Ahren Innovation Capital and will support the expansion of the company's in-house target discovery programme.
"OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected."
The oversubscribed round was led by Oyster Bay Venture Capital to advance research and development on plant-based materials.
"Once optimised and patented, we will raise our next round to co-locate this continuous process alongside a brewery, enabling immense production outputs. We initially applied our technology to beer breweries and whisky distilleries because of their robust supply chains. As part of this raise, we will also prioritise commercial partnerships to introduce products to the fashion and other industries, starting on a small scale."
The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.
"A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe."
The financing round was led by LAUNCHub Ventures and Kadmos Capital to fund the company's shift towards the diagnostics market.
"We are thrilled to have the support of LAUNCHub Ventures and Kadmos Capital, who share our vision for a healthier future. This funding round marks a significant milestone for GlycanAge, and we are excited to continue our journey towards transforming healthcare and empowering individuals to take control of their well-being."
.png)
